Study:
Phase II Evaluation of Early Oral Estramustine, Oral Etoposide and Intravenous Paclitaxel in Combination With Hormone Therapy in Patients With High-Risk Metastatic Adenocarinoma of the Prostate
Rationale:
Drugs used in chemotherapy use different ways to stop tumor cells from dividing
so they stop growing or die. Androgens can stimulate the growth of prostate cancer cells.
Drugs such as goserelin, leuprolide, flutamide, or bicalutamide may stop the adrenal glands
from producing androgens. Combining chemotherapy with hormone therapy may kill more tumor
cells.
Purpose:
Phase II trial to study the effectiveness of combination chemotherapy plus hormone
therapy in treating patients who have metastatic prostate cancer.
Study Status: Active, not recruiting
Recruiting:
n/a
| Condition |
Intervention |
Phase |
|
Prostate Cancer |
Drug: bicalutamide
Drug: estramustine phosphate sodium
Drug: etoposide
Drug: flutamide
Drug: goserelin
Drug: leuprolide acetate
Drug: nilutamide
Drug: paclitaxel |
Phase 2 |
Verified by
Southwest Oncology Group
June, 2011
Sponsored by: Southwest Oncology Group
Information provided by: Southwest Oncology Group
ClinicalTrials.gov identifier: NCT00028769
Study Type: Interventional
Study Design: Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Cleveland Clinic Taussig Cancer Center
Cleveland, Ohio 44195-9001
United States
David C. Smith, MD., Study Chair